Randox Laboratories of Crumlin is to supply its leading edge biochip technology, used in the field of clinical diagnostics, to the prestigious University of Colorado, Health Sciences Centre (UCHSC) Hospital in Denver, Colorado.
The agreement between Randox and the university was announced at the start of an Invest Northern Ireland trade mission to
Denver and San Jose from 17-22 October. Randox is among a 16-strong group of companies taking part in the mission.
UCHSC is renowned as a worldclass, academic health centre which incorporates state-of-the-art healthcare facilities for the provision of healthcare and medical research.
Dr Peter Fitzgerald, Randox managing director, said the introduction of Randox’s fully automated biochip analyser, Evidence® to UCHSC “puts the local company at the forefront of medical diagnosis within the US”.
Dr Fitzgerald added: “We are very excited about the launch of our biochip instrument in UCHSC and consider this to be a strategic location which, together with our other US placements, gives Randox good geographical coverage within the US.
“We have worked closely with the Northern Ireland Technology and Development Centre in Denver to bring about this placement and to select a reference site for Colorado and neighbouring States.
“This technology has significant advantages in routine clinical diagnostics and we envisage that the system, which has applications within blood banking, tissue matching and clinical research, will be widely used by various customers in and around Denver and throughout the State of Colorado.”
Welcoming the Randox announcement, Alan Hingston, Invest NI’s Trade director, said: “This is a further example of how our technology and development centres in the US, where we have facilities in Boston and Denver, and other parts of the world can help Northern Ireland companies to identify opportunities and to make the necessary contacts that will lead to worthwhile business.
“The centres enable Northern Ireland companies to access advice and practical support from business people with significant experience of doing business in the market and a network of contacts. Companies are also able to use the centres as a base when in the market.”
The Randox Evidence® system will be launched at a Bio Symposium at UCHSC during the mission. A number of key Denver and Colorado-based clinical and research organisations will be attending the bio-symposium.
The mission is being led by Frank Hewitt, Northern Ireland Chamber of Commerce and Industry (NICCI) chief executive. NICCI is working with Denver Metro Chamber and the World Trade Centre in Denver to promote trade and business alliances between Northern Ireland and Colorado.
The mission coincides with Colorado State Technology Week and a number of networking events are planned by Invest NI that will enable Northern Ireland companies to meet businesses from the state and further afield.
Medical device companies on the mission will present at the Colorado Bio Entrepreneurs Club Networking Event and a representative of Nanotec NI, the organisation representing Northern Ireland’s nanotechnology capabilities across both universities, will be a key speaker at the National Institute of Standards and Technology’s Nanotechnology Conference, two of the many events being held during Colorado State Technology Week.
Northern Ireland companies will also be taking part in a special networking event with a business delegation from Canada, which will be in Colorado at the same time.
Northern Ireland Companies on the Invest NI Trade Mission to Denver and San Jose from 17-22 October